Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.
Cusatuzumab is a monoclonal antibody that binds with high affinity to CD70, a cell surface protein overexpressed on CD34+ acute myeloid leukemia (AML) progenitors and leukemia stem cells. This phase Ib study assessed the safety, tolerability and efficacy of adding cusatuzumab to standard-of-care azacitidine and venetoc...